Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 6, 2008, Pages 527-535

  Zhu, Yanli ^a   Zhang, Lihong ^a   Gidday, Jeffrey M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON CHELATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE TARGETING; HISTOPATHOLOGY; HYPOXIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; ISCHEMIC PRECONDITIONING; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REPEATED DRUG DOSE; RETINA ISCHEMIA; SINGLE DRUG DOSE;

ADRENOMEDULLIN; ANIMALS; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON CHELATING AGENTS; ISCHEMIA; ISCHEMIC PRECONDITIONING; MALE; MICE; RETINAL VESSELS;

EID: 57349092150     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0082     Document Type: Article

References (53)

1. Roth, S., Li, B., Rosenbaum, P.S., et al. Preconditioning provides complete protection against retinal ischemic injury in rats. Invest. Ophthalmol. Vis. Sci. 39:777-785, 1998.
2. Zhu, Y., Ohlemiller, K.K., McMahan, B.K., et al. Mouse models of retinal ischemic tolerance. Invest. Ophthalmol. Vis. Sci. 43:1903-1911, 2002.
3. Gidday, J.M. Cerebral preconditioning and ischaemic tolerance. Nat. Rev. Neurosci. 7:437-448, 2006.
4. Bergeron, M., Gidday, J.M., Yu, A.Y., et al. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann. Neurol. 48:285-296, 2000.
5. Prass, K., Ruscher, K., Karsch, M., et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J. Cereb. Blood Flow Metab. 22:520-525, 2002.
6. Zhu, Y., Zhang, Y., Ojwang, B.A., et al. Long-term tolerance to retinal ischemia by repetitive hypoxic preconditioning: Role of HIF-1a and heme oxygenase-1. Invest. Ophthalmol. Vis. Sci. 48:1735-1743, 2007.
7. Whitlock, N.A., Agarwal, N., and Ma, J.X. Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest. Ophthalmol. Vis. Sci. 46:1092-1098, 2005.
8. Jiang, B.H., Zheng, J.Z., Leung, S.W., et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272:19253-19260, 1997.
9. Schofield, C.J., and Ratcliffe, P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 338:617-626, 2005.
10. Roth, S. Endogenous neuroprotection in the retina. Brain Res. Bull. 62:461-466, 2004.
11. Nonaka, A., Kiryu, J., Tsujikawa, A., et al. Inhibitory effect of ischemic preconditioning on leukocyte participation in retinal ischemia-reperfusion injury. Invest. Ophthalmol. Vis. Sci. 42:2380-2385, 2001.
12. Zhu, Y., Ohlemiller, K.K., McMahan, B.K., et al. Constitutive nitric oxide synthase activity is required to trigger ischemic tolerance in mouse retina. Exp. Eye Res. 82:153-163, 2005.
13. Ettaiche, M., Heurteaux, C., Blondeau, N., et al. ATP-sensitive potassium channels (K(ATP)) in retina: A key role for delayed ischemic tolerance. Brain Res. 890:118-129, 2001.
14. Roth, S., Dreixler, J.C., Shaikh, A.R., et al. Mitochondrial potassium ATP channels and retinal ischemic preconditioning. Invest. Ophthalmol. Vis. Sci. 47:2114-2124, 2006.
15. Yuan, Y., Hilliard, G., Ferguson, T., et al. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem 278:15911-15916, 2003.
16. Badr, G.A., Zhang, J.Z., Tang, J., et al. Glut1 and glut3 expression, but not capillary density, is increased by cobalt chloride in rat cerebrum and retina. Brain Res. Mol. Brain Res. 64:24-33, 1999.
17. Ke, Q., and Costa, M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70:1469-1480, 2006.
18. Halliwell, B. Protection against tissue damage in vivo by desferrioxamine: What is its mechanism of action? Free Radic. Biol. Med. 7:645-651, 1989.
19. Bell, E.L., Klimova, T.A., Eisenbart, J., et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell Biol. 177:1029-1036, 2007.
20. O'Duffy, A.E., Bordelon, Y.M., and McLaughlin, B. Killer proteases and little strokes - how the things that do not kill you make you stronger. J. Cereb. Blood Flow Metab. 27:655-668, 2007.
21. Farinelli, S.E., and Greene, L.A. Cell-cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci. 16:1150-1162, 1996.
22. Grimm, C., Wenzel, A., Groszer, M., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 8:718-724, 2002.
23. Bernaudin, M., Nedelec, A.S., Divoux, D., et al. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J. Cereb. Blood Flow Metab. 22:393-403, 2002.
24. Sharp, F.R., Ran, R., Lu, A., et al. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 1:26-35, 2004.
25. Dendorfer, A., Heidbreder, M., Hellwig-Burgel, T., et al. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals. Free Radic. Biol. Med. 38:117-124, 2005.
26. Chavez, J.C., and LaManna, J.C. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: Potential role of insulin-like growth factor-1. J. Neurosci. 22:8922-8931, 2002.
27. Stroka, D.M., Burkhardt, T., Desbaillets, I., et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 15:2445-2453, 2001.
28. Jewell, U.R., Kvietikova, I., Scheid, A., et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15:1312-1314, 2001.
29. Berra, E., Richard, D.E., Gothie, E., et al. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett. 491:85-90, 2001.
30. Semenza, G.L. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp. Physiol. 91:803-806, 2006.
31. Sandau, K.B., Zhou, J., Kietzmann, T., et al. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J. Biol. Chem 276:39805-39811, 2001.
32. Brahimi-Horn, C., Mazure, N., and Pouyssegur, J. Signalling via the hypoxia-inducible factor-1alpha requires multiple post-translational modifications. Cell. Signal. 17:1-9, 2005.
33. Junk, A.K., Mammis, A., Savitz, S.I., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 99:10659-10664, 2002.
34. Hegazy, K.A., Dunn, M.W., and Sharma, S.C. Functional human heme oxygenase has a neuroprotective effect on adult rat ganglion cells after pressure-induced ischemia. NeuroReport 11:1185-1189, 2000.
35. Nishijima, K., Ng, Y.S., Zhong, L., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171:53-67, 2007.
36. Kis, B., Abraham, C.S., Deli, M.A., et al. Adrenomedullin in the cerebral circulation. Peptides 22:1825-1834, 2001.
37. Serrano, J., Alonso, D., Fernandez, A.P., et al. Adrenomedullin in the central nervous system. Microsc. Res. Tech. 57:76-90, 2002.
38. Dorner, G.T., Garhofer, G., Huemer, K.H., et al. Effects of adrenomedullin on ocular hemodynamic parameters in the choroid and the ophthalmic artery. Invest. Ophthalmol. Vis. Sci. 44:3947-3951, 2003.
39. Kaneko, Y., Saito, M., Mori, A., et al. Vasodilator effects of adrenomedullin on retinal arterioles in streptozotocin-induced diabetic rats. J. Ocul. Pharmacol. Ther. 22:317-322, 2006.
40. Udono-Fujimori, R., Udono, T., Totsune, K., et al. Adrenomedullin in the eye. Regul. Pept. 112:95-101, 2003.
41. Huang, W., Wang, L., Yuan, M., et al. Adrenomedullin affects two signal transduction pathways and the migration in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 45:1507-1513, 2004.
42. Xia, C.F., Yin, H., Borlongan, C.V., et al. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp. Neurol. 197:521-530, 2006.
43. Chen, L., Kis, B., Busija, D.W., et al. Adrenomedullin protects rat cerebral endothelial cells from oxidant damage in vitro. Regul. Pept. 130:27-34, 2005.
44. Watanabe, K., Takayasu, M., Noda, A., et al. Adrenomedullin reduces ischemic brain injury after transient middle cerebral artery occlusion in rats. Acta. Neurochir. 143:1157-1161, 2001.
45. Miyashita, K., Itoh, H., Arai, H., et al. The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential. Endocrinology 147:1642-1653, 2006.
46. Cormier-Regard, S., Nguyen, S.V., and Claycomb, W.C. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J. Biol. Chem. 273:17787-17792, 1998.
47. Bernaudin, M., Tang, Y., Reilly, M., et al. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J. Biol. Chem. 277:39728-39738, 2002.
48. Gehlbach, P., and Purple, R.L. Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. Invest. Ophthalmol. Vis. Sci. 35:669-676, 1994.
49. Ophir, A., Berenshtein, E., Kitrossky, N., et al. Protection of the transiently ischemic cat retina by zinc-desferrioxamine. Invest. Ophthalmol. Vis. Sci. 35:1212-1222, 1994.
50. Banin, E., Berenshtein, E., Kitrossky, N., et al. Gallium-desferrioxamine protects the cat retina against injury after ischemia and reperfusion. Free Radic. Biol. Med. 28:315-323, 2000.
51. Weinberg, E.D. Therapeutic potential of iron chelators in diseases associated with iron mismanagement. J. Pharm. Pharmacol. 58:575-584, 2006.
52. Porter, J.B. Monitoring and treatment of iron overload: State of the art and new approaches. Semin. Hematol. 42:S14-S18, 2005.
53. Haimovici, R., D'Amico, D.J., Gragoudas, E.S., et al. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109:164-171, 2002.